cagrisema vs tirzepatide obesitymedicine #medicalnews #clinicaltrials #cagrisema #zepbound # #semaglutide #weightloss #healthcare | Joseph Zucchi, PA-C, MPAS CagriSema vs Tirzepatide: 23% Weight

The target trial emulation associated GLP-1 receptor agonist initiation with a higher risk of incident psoriasis compared with DPP-4 inhibitors over up to four years, and the authors highlighted the importance of ongoing skin monitoring

You experience severe abdominal pain or cramping

Oxidative reactions in the tear fluid of patients suffering from dry eyes

They treated 8 pouchees with the GLP-1 drug Liraglutide (trade name Saxenda ) in a well-designed, placebo-controlled, double-blind, cross-over clinical trial and showed a 35% reduction in toilet frequency on treatment compared to placebo, a reduction in urgency and better stool consistency and the drug was safe and well tolerated